OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.

OBJECTIVE To update and expand upon prior OARSI guidelines by developing patient-focused treatment recommendations for individuals with Knee, Hip, and Polyarticular osteoarthritis (OA) that are derived from expert consensus and based on objective review of high-quality meta-analytic data. METHODS We sought evidence for 60 unique interventions. A systematic search of all relevant databases was conducted from inception through July 2018. After abstract and full-text screening by two independent reviewers, eligible studies were matched to PICO questions. Data were extracted and meta-analyses were conducted using RevMan software. GRADE Evidence Profiles were compiled using the GRADEpro web application. Voting for Core Treatments took place first. Four subsequent voting sessions took place via anonymous online survey, during which Panel members were tasked with voting to produce recommendations for all joint locations and comorbidity classes. We designated non-Core treatments to Level 1A, 1B, 2, 3, 4A, 4B, or 5, based on the percentage of votes in favor, in addition to the strength of the recommendation. RESULTS Core Treatments for Knee OA included arthritis education and structured land-based exercise programs with or without dietary weight management. Core Treatments for Hip and Polyarticular OA included arthritis education and structured land-based exercise programs. Topical NSAIDs were strongly recommended for individuals with Knee OA (Level 1A). For individuals with gastrointestinal comorbidities, COX-2 inhibitors were Level 1B and NSAIDs with proton pump inhibitors Level 2. For individuals with cardiovascular comorbidities or frailty, use of any oral NSAID was not recommended. Intra-articular (IA) corticosteroids, IA hyaluronic acid, and aquatic exercise were Level 1B/Level 2 treatments for Knee OA, dependent upon comorbidity status, but were not recommended for individuals with Hip or Polyarticular OA. The use of Acetaminophen/Paracetamol (APAP) was conditionally not recommended (Level 4A and 4B), and the use of oral and transdermal opioids was strongly not recommended (Level 5). A treatment algorithm was constructed in order to guide clinical decision-making for a variety of patient profiles, using recommended treatments as input for each decision node. CONCLUSION These guidelines offer comprehensive and patient-centered treatment profiles for individuals with Knee, Hip, and Polyarticular OA. The treatment algorithm will facilitate individualized treatment decisions regarding the management of OA.

[1]  K. Vowles,et al.  Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis , 2015, Pain.

[2]  P. Libby,et al.  Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. , 2016, The New England journal of medicine.

[3]  K. Kroenke,et al.  Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial , 2018, JAMA.

[4]  L. Nartey,et al.  Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis , 2017, The Lancet.

[5]  P Tugwell,et al.  OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. , 2008, Osteoarthritis and cartilage.

[6]  S. Kingsbury,et al.  Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries. , 2014, Rheumatology.

[7]  D. Ashby,et al.  Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study. , 2008, Health technology assessment.

[8]  A Thomas McLellan,et al.  Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies. , 2016, The New England journal of medicine.

[9]  David Rind,et al.  GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. , 2013, Journal of clinical epidemiology.

[10]  Deborah Schofield,et al.  The individual and socioeconomic impact of osteoarthritis , 2014, Nature Reviews Rheumatology.

[11]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[12]  R. Garner,et al.  Productivity costs of work loss associated with osteoarthritis in Canada from 2010 to 2031. , 2017, Osteoarthritis and cartilage.

[13]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[14]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[15]  T. Vos,et al.  The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study , 2014, Annals of the rheumatic diseases.

[16]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[17]  P. Libby,et al.  Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis , 2018, Arthritis & Rheumatology.

[18]  Gerta Rücker,et al.  Bmc Medical Research Methodology Open Access Undue Reliance on I 2 in Assessing Heterogeneity May Mislead , 2022 .

[19]  K. Juel,et al.  Chronic non‐cancer pain and the epidemic prescription of opioids in the Danish population: trends from 2000 to 2013 , 2016, Acta anaesthesiologica Scandinavica.

[20]  V. Welch,et al.  Oral or transdermal opioids for osteoarthritis of the knee or hip. , 2009, The Cochrane database of systematic reviews.

[21]  S. Bierma-Zeinstra,et al.  Productivity costs and medical costs among working patients with knee osteoarthritis , 2012, Arthritis care & research.

[22]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[23]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[24]  E. Hess,et al.  Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study , 2018, British Medical Journal.

[25]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[26]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[27]  C. Le Pen,et al.  Financial cost of osteoarthritis in France. The "COART" France study. , 2005, Joint, bone, spine : revue du rhumatisme.

[28]  T. Schnitzer,et al.  Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials , 2013, BDJ.

[29]  S Lohmander,et al.  OARSI guidelines for the non-surgical management of knee osteoarthritis. , 2014, Osteoarthritis and cartilage.

[30]  M. Hochberg,et al.  Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. , 2015, Osteoarthritis and cartilage.

[31]  E. Roughead,et al.  Prevalence and changes in analgesic medication utilisation 1 year prior to total joint replacement in an older cohort of patients. , 2017, Osteoarthritis and cartilage.

[32]  D. Hunter,et al.  Too much opioid, too much harm. , 2017, Osteoarthritis and cartilage.

[33]  J. Katz,et al.  Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. , 2016, Osteoarthritis and cartilage.

[34]  M. Egger,et al.  Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis , 2011, BMJ : British Medical Journal.

[35]  P. McGettigan,et al.  Differences in cardiovascular safety with non‐steroidal anti‐inflammatory drug therapy—A nationwide study in patients with osteoarthritis , 2019, Basic & clinical pharmacology & toxicology.

[36]  J. Brophy,et al.  Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data , 2017, British Medical Journal.